Rheumatology 2001; 40: 37-47
© 2001 British Society for Rheumatology
Total costs and predictors of costs in patients with systemic lupus erythematosus
Centre for Rheumatology/Bloomsbury Rheumatology Unit, Department of Medicine, University College London, UK
1 Divisions of Clinical Immunology/Allergy and Clinical Epidemiology, Montreal General Hospital, McGill University, Montreal, Quebec, Canada
2 Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London University, London, UK
Objective. To determine the annual direct, indirect and total costs and predictors of costs in patients with systemic lupus erythematosus (SLE).
Methods. One hundred and five patients with SLE completed questionnaires on health-care utilization and employment history. Predictors of costs were determined by multiple regression analyses using direct, indirect and total costs as outcome variables. Demographics, health status, disease activity, end-organ damage, social support and satisfaction with care were used as predictor variables.
Results. The mean annual total cost per patient was £7913. Direct costs were a third and indirect costs two-thirds of the total cost. Higher education level, greater disease activity and lower physical functioning were associated with higher direct, indirect and total costs. Higher direct costs were also associated with greater damage and younger age.
Conclusion. SLE has a considerable impact on the health-care system and society. Improvement in disease activity and physical health and prevention of end-organ damage may reduce costs in SLE.
KEY WORDS: SLE, Direct costs, Indirect costs, Total costs, Predictors of costs.
Correspondence to: N. Sutcliffe, Centre for Rheumatology, Bloomsbury Rheumatology Unit, Arthur Stanley House, 4th Floor, 40–50 Tottenham Street, London W1P 9PG, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Baker, J. Pope, P. Fortin, E. Silverman, C. Peschken, and 1000 Faces of Lupus Investigators and CaNIOS (Cana Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factors Lupus, December 1, 2009; 18(14): 1281 - 1288. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Y. Zhu, L.-S. Tam, V. W. Y. Lee, K. K. Lee, and E. K. Li Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong Rheumatology, May 1, 2009; 48(5): 564 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Baker and J. Pope Employment and work disability in systemic lupus erythematosus: a systematic review Rheumatology, March 1, 2009; 48(3): 281 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. F. Wilson, D. R. W. Jayne, E. Dellow, and R. J. Fordham The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis Rheumatology, July 1, 2007; 46(7): 1096 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Callaghan, A. Prabu, R. B. Allan, A. E. Clarke, N. Sutcliffe, Y. St. Pierre, C. Gordon, S. J. Bowman, and the UK Sjogren's Interest Group Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome Rheumatology, January 1, 2007; 46(1): 105 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Boonen, D van der Heijde, R Landewe, A Spoorenberg, H Schouten, M Rutten-Van Molken, F Guillemin, M Dougados, H Mielants, K de Vlam, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries Ann Rheum Dis, May 1, 2002; 61(5): 429 - 437. [Abstract] [Full Text] [PDF]
|
|